Premixed Insulin Analogue Compared with Basal-Plus Regimen for Inpatient Glycemic Control

Gracia‐Ramos, Abraham Edgar; Pilar, Cruz-DomínguezMaría del; Osiris, Madrigal-SantillánEduardo; Morales-González, José A.; Madrigal-BujaidarEduardo,; Aguilar-Faisal, Leopoldo

doi:10.1089/dia.2016.0176

Cited by 11 publications

(15 citation statements)

References 41 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Study populations ranged from 50 to 890 patients, with the shortest follow-up lasting just 8 days and the longest 60 weeks. The basal-plus regimen was composed of insulin glargine 100 U/mL (IGlar) and insulin glulisine (IGlu) in 11 studies (13/18 manuscripts),8 9 13 15–24 IGlar and insulin lispro (ILis) in 2 studies (3/18 manuscripts)14 25 26 and insulin detemir (IDet) and insulin aspart (IAsp) in 2 studies (2/18 manuscripts) 27 28…”

Section: Resultsmentioning

confidence: 99%

Addition of a single short-acting insulin bolus to basal insulin-supported oral therapy: a systematic review of data on the basal-plus regimen

Seufert

Borck

Bramlage

2019

BMJ Open Diab Res Care

View full text Add to dashboard Cite

We summarize here clinical and trial data on a once-daily administration of a single bolus to the meal with the largest expected postprandial glucose excursion (basal-plus), and comment on its clinical utility in the treatment of type 2 diabetes. A PubMed search of data published until September 2018 was taken into consideration and PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) guidelines were followed. Eighteen reports representing 15 studies were identified (age: 18–80 years; 50–890 patients; follow-up: 8 days to 60 weeks). Data suggest basal-plus is efficacious for improving glycemic control, with a low incidence of (severe) hypoglycemia and minor increases in bodyweight. The timing of short-acting insulin administration and use of different monitoring/titration approaches appear to have minimal impact. When compared with premixed insulin, basal-plus results in largely comparable outcomes. Compared with basal-bolus, it may result in non-inferior glycemic improvements with less weight gain, less hypoglycemia and fewer daily injections. A basal insulin/glucagon-like peptide-1 receptor agonist fixed ratio combination may offer several advantages over the basal-plus regimen, at the cost of gastrointestinal side effects. We conclude that the stepwise introduction of short-acting insulin via the basal-plus strategy represents a viable alternative to a full basal-bolus regimen and may help to overcome barriers associated with multiple injections and anticipated complexity of the insulin regimen.

show abstract

Section: Resultsmentioning

confidence: 99%

Addition of a single short-acting insulin bolus to basal insulin-supported oral therapy: a systematic review of data on the basal-plus regimen

Seufert

Borck

Bramlage

2019

BMJ Open Diab Res Care

View full text Add to dashboard Cite

show abstract

“…Una serie de 99 casos reportados en la Clínica Mayo3 reportó una edad promedio de 51 años (rango: 30-83), siendo el 63 % varones. El acrónimo POEMS fue establecido por Bardwick en 1980, el cual se refiere a las características del síndrome: poliradiculoneuropatía, organomegalia, endocrinopatía, desorden monoclonal de células plasmáticas y cambios cutáneos [1][2][3] . Hay tres puntos importantes relacionados con este acrónimo: 1) No se requieren todas las características para el diagnóstico; 2) Existen otras características no incluidas en el acrónimo, incluyendo papiledema, sobrecarga de volumen extravascular, lesiones óseas escleróticas, trombocitosis/eritrocitosis (PEST), así como niveles elevados del VEGF, predisposición hacia la trombosis y pruebas de función pulmonar alteradas; 3) Puede asociarse a un desorden clonal de células plasmáticas; y 4) Existe una variante asociada a la enfermedad de Castleman3 Dispenzieri sugiere un conjunto de criterios obligatorios, importantes, y menores [2][3][4] .…”

Section: Introductionunclassified

“…La enfermedad de Castleman (también conocida como hiperplasia ganglionar angiofolicular, hiperplasia linfoide gigante, hamartoma linfoide o linforreticuloma folicular) es un trastorno linfoproliferativo atípico de causa desconocida, caracterizado por crecimiento ganglionar hiperplásico no clonal 4 . En 1954 fue descrita por Benjamin Castleman, quien posteriormente la definió en una serie de 13 casos 1 . Se reconoce una mayor prevalencia en hombres con una relación 2:1, entre la quinta y sexta década de la vida 3,4 .…”

Section: Introductionunclassified

“…Existen tres variedades histológicas: hialina vascular, de células plasmáticas, y mixta. Asimismo, existen dos formas clínicas: localizada y multicéntrica 1,3 . En la forma localizada hay solo un sitio de afección ganglionar: mediastino (60-75%), cuello (20%) o abdomen (10%); generalmente es asintomática o con síntomas relacionados al efecto de masa.…”

Section: Introductionunclassified

“…Generalmente se acompaña de síntomas sistémicos como fiebre, diaforesis nocturna, fatiga, anorexia, pérdida de peso. Esta forma requiere tratamiento sistémico y el rango de supervivencia es de 14-30 meses 1,5 .…”

Section: Introductionunclassified

See 2 more Smart Citations

Síndrome Poems Asociado a Enfermedad De Castleman. Un Reporte De Caso

Sotelo-Jiménez

Ramírez-Calderón

Quiñones-Avila

2019

RFMH

View full text Add to dashboard Cite

POEMS (Polineuropatía, Organomegalia, Endocrinopatía, Proteína Monoclonal y cambios en la piel) es un trastorno multisistémico raro. La enfermedad de Castleman es un trastorno linfoproliferativo atípico de causa desconocida, que puede estar asociado a POEMS. Paciente mujer de 37 años de edad con cuadro clínico de 2 años de evolución caracterizado por múltiples adenopatías, adormecimiento, y debilidad de extremidades inferiores asociado a hiperpigmentación cutánea e hipertricosis. La electromiografía muestra una polineuropatía crónica activa, sensitiva-motora de tipo axonal; y la electroforesis sérica mostró banda monoclonal de Inmunoglobulina A tipo lambda. La biopsia de ganglio submandibular fue compatible con Enfermedad de Castleman. Este reporte resalta el hecho que la enfermedad de Castleman se presenta en forma frecuente como parte de una variante del síndrome POEMS, y debe ser descartado en estos pacientes. Asimismo, la plasmaféresis puede ser útil en pacientes con síntomas neurológicos severos.

show abstract

Real-world clinical outcomes and costs in type 2 diabetes mellitus patients after initiation of insulin therapy: A German claims data analysis

Gabler

Picker

Geier

et al. 2021

Diabetes Research and Clinical Practice

View full text Add to dashboard Cite

Background: This study describes real-world treatment-related outcomes and healthcare costs of German type 2 diabetes mellitus (T2D) patients who initiated insulin therapy. Methods: This retrospective analysis includes German claims data from 01/01/2012 until 31/12/2016. Identification of eligible patients took place between 01/01/2013 and 31/12/2015, allowing for at least 1 year of follow-up. Clinical outcomes, such as HbA1c values and body mass index, were observed in a subpopulation participating in a Disease Management Program. Healthcare expenditures were evaluated for the first year of therapy. Results: Overall, 27,340 insulin starters with T2D were observed (mean age: 72.2 years, female: 51.4%). Treatment-related outcomes were evaluated in a subsample of 12,034 patients. Patients who started insulin combined with other antidiabetic drugs (ADs) achieved their HbA1c goals more frequently than patients on insulin monotherapy (+10.7 percentage points [pp] vs. +21.1 pp for insulin plus metformin). All-cause costs were by far highest among patients with insulin monotherapy (€ 12,283 per patient-year) compared with patients receiving a combined AD regimen (€ 9,947-10,509 per patient-year). Conclusions: Changes in HbA1c values were not in favor of insulin monotherapy, compared to regimens including other ADs. It was also associated with higher costs, suggesting that insulin alone is a suboptimal treatment.

show abstract

Premixed Insulin Analogue Compared with Basal-Plus Regimen for Inpatient Glycemic Control

Abstract: Results of this trial indicate that the use of a premixed insulin analogue is as effective and safe as the basal-plus regimen to achieve glycemic control.

Cited by 11 publications

References 41 publications

Addition of a single short-acting insulin bolus to basal insulin-supported oral therapy: a systematic review of data on the basal-plus regimen

Addition of a single short-acting insulin bolus to basal insulin-supported oral therapy: a systematic review of data on the basal-plus regimen

Síndrome Poems Asociado a Enfermedad De Castleman. Un Reporte De Caso

Real-world clinical outcomes and costs in type 2 diabetes mellitus patients after initiation of insulin therapy: A German claims data analysis

Contact Info

Product

Resources

About